Vigil Neuroscience is delighted to announce a significant funding milestone with a remarkable raise of $470,000,000. This monumental investment underscores both the conviction of our financial partners and the scientific community in our innovative approach to treating neurodegenerative diseases. As a clinical-stage biotechnology company, we are committed to transforming the therapeutic landscape by targeting both rare and common neurodegenerative conditions through the restoration of microglial vigilance—an essential function provided by the brain’s sentinel immune cells. Our focus on precision-based therapies is anchored in this pioneering strategy, employing modern neuroscience drug development techniques across multiple therapeutic modalities.
The funding will accelerate the clinical advancement of our lead candidate, VGL101, a fully human monoclonal antibody agonist targeting triggering receptor expressed on myeloid cells 2 (TREM2) in patients suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Additionally, these resources will support our efforts in developing VG-3927, a novel small molecule TREM2 agonist designed to address the underlying microglial dysfunction in common neurodegenerative ailments such as Alzheimer’s disease, particularly within genetically defined subpopulations.
This capital infusion not only strengthens our research and development capabilities but also accelerates our commitment to improving the lives of patients and their families. By harnessing the power of advanced neuroscience, Vigil Neuroscience is poised to lead the way in delivering transformative therapies, offering hope and improved outcomes where there were once limited options. We are excited for the road ahead and remain steadfast in our mission to redefine the future of neurodegenerative disease treatment.
